Damora Therapeutics Financials - Benzinga

Damora Therapeutics Inc

DMRANASDAQ

Trade with Public

Trade with Public

$22.59

-0.19-0.83%

At close: Sep 18, 5:00 PM EST

$22.19

-0.40-1.77%

After Hours: 5:46 PM EST

Overview News Earnings Forecast Price TargetsFinancialsSentiment Ownership Compare Stock Report

Damora Therapeutics Financials

Damora Therapeutics (DMRA) financial statements — income, revenue, gross margin and key metrics.

Earnings & Guidance News

PRO
Damora Therapeutics Q2 EPS $(0.39) Beats $(0.43) Estimate

Damora Therapeutics (NASDAQ:DMRA) reported quarterly losses of $(0.39) per share which beat the analyst consensus estimate of $(0.43) by 9.3 percent. This is a 85 percent increase over losses of $(2.60) per share from

Benzinga Newsdesk

PRO
Damora Therapeutics Q1 EPS $(0.62) Misses $(0.40) Estimate

Damora Therapeutics (NASDAQ:DMRA) reported quarterly losses of $(0.62) per share which missed the analyst consensus estimate of $(0.40) by 55 percent. This is a 67.71 percent increase over losses of $(1.92) per share

Benzinga Newsdesk

PRO
Damora Therapeutics FY2025 EPS $3.98 Up From FY2024 EPS $(18.53)

Benzinga Newsdesk